Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous group of neuroendocrine neoplasms with varying biological behavior and response to treatment. Although targeted therapies have been shown to improve the survival for patients at advanced stage, resistance to current therapies frequently occurs during the course of therapy. Previous reports indicate that the infiltration of tumor-associated macrophages (TAMs) in PNETs might correlate with tumor progression and metastasis formation. We aimed to evaluate the prognostic and functional impact of TAMs in human PNETs in vitro and in vivo and to investigate the effect of therapeutic targeting TAMs in a genetic PNET mouse model. TAM expression pattern was assessed immunohistochemically in human PNET tissue sections and a tissue-micro-array of PNET tumors with different functionality, stage, and grading. The effect of liposomal clodronate on TAM cell viability was analyzed in myeloid cell lines and isolated murine bone macrophages (mBMM). In vivo, RIP1Tag2 mice developing insulinomas were treated with liposomal clodronate or PBS-Liposomes. Tumor progression, angiogenesis and immune cell infiltration were assessed by immunohistochemistry. In human, insulinomas TAM density was correlated with invasiveness and malignant behavior. Moreover, TAM infiltration in liver metastases was significantly increased compared to primary tumors. In vitro, Liposomal clodronate selectively inhibited the viability of myeloid cells and murine bone macrophages, leaving PNET tumor cell lines largely unaffected. In vivo, repeated application of liposomal clodronate to RIP1Tag2 mice significantly diminished the malignant transformation of insulinomas, which was accompanied by a reduced infiltration of F4/80-positive TAM cells and simultaneously by a decreased microvessel density, suggesting a pronounced effect of clodronate-induced myeloid depletion on tumor angiogenesis. Concomitant treatment with the antiangiogenic TKI sunitinib, however, did not show any synergistic effects with liposomal clodronate. TAMs are crucial for malignant transformation in human PNET and correlate with metastatic behavior. Pharmacological targeting of TAMs via liposomal clodronate disrupts tumor progression in the RIP1Tag2 neuroendocrine tumor model and was associated with reduced tumor angiogenesis. Based on these results, using liposomal clodronate to target proangiogenic myeloid cells could be employed as novel therapeutic avenue in highly angiogenic tumors such as PNET.
During the last decade, the predominant role of the tumor microenvironment (TME) as modulator of tumor progression has been increasingly recognized. Nonmalignant stromal cells not only may facilitate tumor initiation, disease progression and metastasis, but also are affecting response or resistance to various therapeutic strategies. The TME comprises stromal cells such as endothelial cells, fibroblasts as well as various immune cell populations. 1 Both lymphoid and myeloid lineages are modulating tumorigenesis and tumor progression, with impact on tumor cell proliferation, invasion and survival as well as effects on the immunogenicity of the tumor. 2, 3 Within the myeloid compartment, tumor-associated macrophages (TAMs) represent an important fraction. Numerous studies have demonstrated an inverse correlation between patient prognosis and TAM infiltration in various tumor entities, among them Hodgkin's lymphoma, breast cancer, glioblastoma and pancreatic cancer. [4] [5] [6] [7] The functional impact of TAMs is still incompletely understood. TAMs release miscellaneous cytokines and proteases, among them proangiogenic factors such as VEGF as well as various cathepsins. [8] [9] [10] Further paracrine mechanisms mediating the cross-talk between TAMs and tumor cells include activation of the epidermal growth factor receptor (EGFR), colony stimulating factor 1 receptor (CSF-R1) and WNT signaling pathways which facilitate tumor cell migration and invasiveness. [11] [12] [13] In addition to their profound effects on tumor progression, TAMs equally affect the efficacy of cancer therapy. For example, TAMs influence the activity of cytidine deaminase (CDA), the key metabolizer of gemcitabine, thereby driving resistance to gemcitabine-based chemotherapy. 14 In addition, also the effects of therapeutic irradiation and targeted antiangiogenic treatment are modulated by TAMs which may acquire different functional states during tumor initiation, progression and therapeutic intervention. TAM functional plasticity has been categorized in two different opposing polarization states, namely, M1 and M2. Generally, M1 macrophages secrete proinflammatory cytokines with antineoplastic effects while M2 macrophages produce anti-inflammatory signals which facilitate tumor progression. 15, 16 However, it is noteworthy that this classification is oversimplified and does not fully represent the complexity of TAM action. Pancreatic neuroendocrine tumors (PNETs) represent a heterogeneous tumor entity within the group of neuroendocrine neoplasms. From a clinical point of view, patients with functionally active PNETs (FA-PNETs) such as insulinomas are mainly diagnosed at early stages, whereas nonfunctional PNETs (NF-PNETs) often present with symptoms when distant metastases have already occurred. 17 Several clinicopathological features have been linked to poor overall survival, including performance status, age, differentiation and proliferation capacity (Ki-67 index). [18] [19] [20] In recent years, effort has been made in deciphering the genetic basis of PNETs. Commonly mutated genes include MEN1, DAXX, ATRX and members of the mTOR pathway. 21 Recently, whole-genome sequencing results of >100 PNETs were presented by Scarpa et al. In this landmark paper, novel germline mutations in the genes MUTYH, CHEK2 and BRCA2 were described. 22 Moreover, distinct subgroups with altered somatic mutations were identified, including chromatin remodeling, DNA damage repair, activation of mTOR signalling (DEPDC5 and EWSR1) and telomere modification. 22 The influence of infiltrating immune cells in neuroendocrine tumors has not been completely elucidated yet. In humans, infiltration of TAMs in primary PNETs correlates with proliferative activity, presence of liver metastases and disease recurrence after curative surgery. 23, 24 Preclinical studies to decipher the role of immune cells were performed using the RIP1Tag2 genetically engineered mouse model for pancreatic neuroendocrine tumors. This model faithfully recapitulates the multistep process of insulinoma transformation, including the stages of hyperplastic islets, angiogenic islets and invasive tumors with various gradings. 25 When tissue-bound macrophages were constitutively depleted in RIP1Tag2 mice via genetic CSF-1 deficiency, the tumor burden decreased markedly. 23 Mechanistically, TAMs modulate the tumor micromilieu via secreting multiple mediators of angiogenesis and invasiveness such as VEGF, heparanase and cathepsins. 9, [26] [27] [28] To overcome TAM mediated disease progression, clinically feasible therapeutics are mandatory. To this end, we utilized liposomal clodronate as pharmacological tool to target TAMs in the RIP1Tag2 model. Moreover, in two large series of FAand NF-PNETs and in primary and distant metastatic sites, CD68-positive macrophages were assessed to study the association between TAM infiltration and tumor progression in humans.
Material and Methods

Material and cell lines
Human neuroendocrine Bon-1 and QGP1 cells were a kind gift of R. G€ oke, University of Marburg, Germany 29 (passage 10-30) and cultured in DMEM/HAM's F12 medium. J774 and RAW cells were obtained by ATCC and cultured in Dulbecco's modified Eagle's medium (GIBCO) supplemented with 10% FCS. All media contained 10% fetal bovine serum and 40 lg/ml gentamicin. All cells were cultured in a humidified atmosphere containing 5% CO 2 at 378C.
Immunohistochemistry, construction of tissue arrays and evaluation
Ki-67 proliferation index was evaluated according to a standardized protocol using Leica-Bond-Max-Autostainer and the Ki-67 antibody from Dako at a dilution of 1:1000. In addition, CD31 (1:20; Dianova; Hamburg, Germany) and CD68 (Dako, 1:100) antibodies were used. Antibody binding was visualized using a biotinylated secondary antibody, avidinconjugated peroxidase (ABC method; Vector Laboratories), Transgenic mouse model and treatments. The RIP1Tag2 transgenic mouse model has been previously described. 25, 30, 31 RIP1Tag2 mice were generated and maintained in a C57BL/6 background. No glucose-enriched food or water was offered to diminish the risk of hypoglycemia. Liposomal clodronate and PBS-Liposomes were obtained from Dr N. Van Rooijen (Vrije Universiteit, Amsterdam, Netherlands). Liposomal clodronate was injected intraperitoneally twice per week at concentrations of 1.4 mg/20 mg body weight. Sunitinib malate was purchased from Cayman chemical (Ann Arbor, USA) and administered daily by oral gavage at concentrations of 40 mg/kg/d. All animal experiments were approved by the local government authorities and performed according to the guidelines of the animal welfare committee.
Statistical design and analysis. The comparisons between macrophage infiltration, tumor response and histopathological characteristics, disease stage and laboratory features were performed based on v 2 and Fisher's exact tests, as appropriate. Recurrence-free survival was measured from surgery to recurrence, disease-related death, or last follow-up. OS was measured from the beginning of treatment to the time of last follow-up or death. Actuarial survival was measured by the method of Kaplan and Meier. 32 All data are presented as mean 6 standard error deviation. Two-tailed paired Student's t test was used for statistical evaluation of the data. The oneway and nonparametric ANOVA test was used to calculate the p values for more than two groups. A p value <0.05 was considered significant. All statistical calculations were performed using SPSS (IBM SPSS Statistics) and graph pad prism (GraphPad software, La Jolla, CA).
Results
Impact of TAMs in functional-(FA) and functional nonactive (NF) PNETs
TAM infiltration was initially assessed in a cohort of PNET tissues including 21 insulinomas as well as 11 nonmetastatic NF tumors and 13 metastatic NF tumors (among them 14 metastases and 4 primary tumors) (Fig. 1a) . Baseline characteristics of all patients within this cohort are given in Table  1 . As expected due to earlier presentation with symptoms, insulinoma patients were younger than NF-PNET patients, which was independent of the presence or absence of distant metastases (median age: 48 vs. 54 vs. 58 years, Table 1 ). Likewise, higher grading significantly correlated with metastatic behavior (G1 1 metastatic vs. 9 nonmetastatic, G2 12 metastatic vs. In subgroup analyses, no correlations between TAM infiltration and patient age, tumor grading, Ki-67 or recurrencefree survival were detected, most likely due to small and heterogeneous sample sizes. Thus, we decided to assess TAM infiltration in an independent larger cohort. For this purpose, a multiple tissue array (MTA) was used comprising 83 tissue with benign and malignant insulinomas and normal peritumoral exocrine pancreatic tissues as internal controls. Histopathological characteristics of the patients are presented in Supporting Information, Table 1 . The median age of the entire cohort was 50 years. The cohort included more males than females affected by insulinomas (68%). Twelve patients with neuroendocrine carcinomas and 48 patients with welldifferentiated tumors and/or metastases were included. The mean density of TAMs was 29, 43 and 234 CD681 cells/10 HPF in peritumoral exocrine pancreas, benign and malignant insulinomas, respectively (Fig. 2b , p < 0.001), indicating a significant correlation between increased macrophage infiltration and tumor progression (Fig. 2a) . The group of malignant insulinomas comprised 7 primary tumors, 5 infiltrated lymph nodes and 7 liver metastases. The highest infiltration of TAMs has been detected in liver metastases with a mean of 315 CD681 cells/10 HPF (p < 0.05 compared to primary tumors and lymph nodes with 178 and 145 CD681 cells, respectively). Moreover, the infiltration of CD681 cells was significantly higher in malignant compared to benign insulinomas (43 vs. 178; p < 0.01, Fig. 2b) . Similarly, poor differentiation defined as G3 neuroendocrine carcinomas (NEC) was associated to higher CD681 macrophage infiltration compared to well-differentiated tumors (NEC vs. NET, 243 vs. 40 CD681 cells, p < 0.0001). The clinical correlation of these findings showed that in 6 out of 12 patients with NEC, a disease-related death (DRD) occurred with a median overall survival of 27 months. In these patients, the CD68 score reached 303 positive cells on average. No DRD was documented in the group of patients with well-differentiated tumors.
Taken together, these results obtained from two independent cohorts demonstrate that TAMs positively correlate with tumor progression, metastatic behavior and poor outcome.
TAMs in a genetically modified mouse model
To better understand the distinct functions of TAMs during neuroendocrine tumorigenesis, we used the RIP1Tag2 transgenic mouse model, which faithfully recapitulates the stepwise progression of pancreatic neuroendocrine tumors. In this model, the p53 and RB (retinoblastoma) tumor suppressor genes are suppressed by SV40-T-antigen in the pancreatic islet cells under the control of the insulin promoter, mediating the sequential progression from hyperplastic islets via angiogenic islets to various grades of invasive tumors. 25 To investigate a possible association between TAMs and PNET progression, we assessed TAM infiltration via F4/80 staining, the Ki-67 index and microvessel density via CD31 staining during the course of disease. and 85 (invasive tumors) (Supporting Information, Fig. 1b ; p < 0.001), indicating an increasing infiltration of TAMs during the tumor progression. Taken together, these results suggest a pivotal role of TAMs during tumorigenesis in PNETs and underline the suitability of the RIP1Tag2 model for therapeutic studies.
Liposomal clodronate targets myeloid cells in vitro and in vivo
Based on the immunohistochemical data indicating an important role of TAMs in tumorigenesis and tumor progression of both human and murine PNET, we aimed to elucidate the impact of therapeutic TAM modulation on tumor progression. For this purpose, liposomal clodronate has been used as an effective pharmacological tool to deplete macrophages in various in vivo models including a mouse model of pancreatic adenocarcinomas. 33 After systemic injection, liposomes are ingested by macrophages followed by intracellular release of clodronate and accumulation of clodronate leading to subsequent apoptosis of the macrophage. 33 To evaluate the specificity of liposomal clodronate to target TAMs, we first investigated the susceptibility of several murine myeloid cell lines and human pancreatic neuroendocrine tumor cell lines to liposomal clodronate in vitro. To this extent, the myeloid cell lines J774, RAW and primary murine bone marrow-derived macrophages (mBMMs) from non-transgenic C57BL/6 mice as well as the neuroendocrine tumor cell lines Bon-1 and GQP1 were utilized. While no effect on cell viability was detected in the tumor cell lines, liposomal clodronate significantly affected cell viability of all investigated myeloid cells with a reduction of cell viability ranging between 39% and 87% after 24 hr (Fig. 3) .
In vivo studies to evaluate the impact of liposomal clodronate on PNET tumorigenesis and tumor progression were performed using the transgenic RIP1Tag2 model. Based on the multistage tumor progression in this model, we used two different pharmacological intervention schemes with liposomal clodronate that allowed us to assess its effects both on the angiogenic switch during tumorigenesis ("prevention trial") and on the tumor progression ("intervention trial"). In the prevention trial, mice harboring normal and hyperplastic islets were treated from Week 6 to 13, while in the intervention trial mice were treated from Week 9 to 16 (Fig. 4a) . Liposomal clodronate effectively decreased the number F4/ 801 macrophages during tumor progression as shown in Supporting Information, Figure 2 . In the prevention trial, liposomal clodronate reduced the cumulative tumor burden at Week 13 significantly by 62% compared to PBS-liposomes (6.9 3 10 6 mm 2 vs. 2.6 3 10 6 mm 2 ; p 5 0.036, Table 2 ). While the number of hyperplastic, angiogenic and invasive islets remained unchanged in both groups, clodronate completely prevented the development of invasive tumors in 4 of 10 mice (p 5 0.025).
In the intervention trial, the influence of liposomal clodronate on tumor progression (number of invasive tumors: mean 4.6 vs. we speculated that TAMs are particularly important in early tumorigenesis during the progression from angiogenic to invasive islets. To further address this hypothesis, we assessed microvessel density (MVD) as cardinal feature of the angiogenic switch using CD31 immunhistochemistry as well as proliferation (Ki-67) and apoptosis marker (cleaved caspase-3). No differences between verum and placebo-treated animals were detected for Ki-67 and cleaved caspase-3 ( Table   2 ). In contrast, CD311 cells in invasive tumors were dramatically diminished in the intervention trial (39 vs. 22 positive cells per HPF, p 5 0.006) with a similar trend also in the prevention trial (77 vs. 48 positive cells per HPF, p 5 0.08). This indicates that angiogenesis is a critical step in mediating progression to invasive tumors, which is affected by macrophage depletion using liposomal clodronate. To characterize the depletion of F4/801 cells more thoroughly, particularly effects on macrophage polarization, we assessed arginase expression by immunohistochemistry as established marker for the protumoral M2 polarization of macrophages. Interestingly, no change was seen between liposomal clodronate and PBS-liposomes treated mice, indicating that both M1 and M2 polarized macrophages are targeted by lipocomal clodronate.
As depletion of F4/801 macrophages may also affect T cell populations, we also stained the T cell marker CD3 and the marker for regulatory T cells FOXP3. In late tumor stages, clodronate application fostered the infiltration of CD3-positive cells (mean: 9 vs. 15 positive cells per HPF, p 5 0.034) in the intervention group. However, at earlier tumor stages, this effect was not present and FOXP3-positive T cells were not regulated in both prevention and intervention cohorts (Table 2 ). Supporting Information, Figure 3 depicts the representative staining of caspase 3, CD3, FOXP3 and arginase in different tumor stages and lymphnodes.
Dual antiangiogenic therapy with sunitinib in combination with liposomal clodronate
In 2011, the antiangiogenic multikinase inhibitor sunitinib has been approved for the treatment of advanced PNETs. 34 However, primary or acquired resistances frequently limit the efficacy of systemic antiangiogenic therapies in PNET patients during the course of the disease. In preclinical models including the RIP1Tag2 mouse model previous reports proposed sunitinib-induced activation of escape mechanisms such as hypoxia, epithelial-mesenchymal transition (EMT) and other hypoxia-dependent signaling pathways [35] [36] [37] as mediators of resistance, thereby accelerating tumor aggressiveness and metastasis formation. Based on these data, we aimed to examine whether these escape mechanisms to antiangiogenic drugs can be overcome by targeting macrophages (Fig. 4b) .
First, we treated RIP1Tag2 mice with sunitinib monotherapy from Week 12 to 16. Thereby, we could confirm that sunitinib resulted in remarkable reduction of microvessel density measured using an Anti-CD31 antibody (Table 3) . However, no differences could be detected in terms of tumor number and volume (Table 3) . In contrast to previous reports no liver metastases could be detected by H&E staining and immunohistochemistry using an SV40 antibody (data not shown). However, in the sunitinib group, all mice (n 5 10) survived the treatment period, whereas 2 of 10 mice in the placebo cohort died before sacrifice, potentially emphasizing a biochemical response during therapy via reducing insulin levels, although statistical significance was not reached due to small sample size.
Furthermore, we depleted macrophages via liposomal clodronate from Week 9 to 16 and simultaneously administered sunitinib (from Week 12 to 16). Combination treatment resulted in a significant reduction of both microvessel density (mean: 39 vs. 15 positive cells per HPF, p < 0.001) and infiltrating TAMs (mean: 47 vs. 24 positive cells per HPF, p 5 0.003) (Table 3) . However, no statistically significant Cancer Therapy and Prevention synergies of dual antiangiogenic treatment regarding number of invasive islets or tumor volumes compared to monotherapy could be detected. Similarly, no differences in proliferation and apoptosis markers or infiltrating CD31, FOXP31 or Arginase1 cells have been observed between combination and monotherapy strategies (Table 3 ). Similar to sunitinib monotherapy more mice reached the study endpoint of 16 weeks in the combination arm (9 vs. 6) compared to placebo therapy; however, this study has not been designed to evaluate overall survival.
Discussion
In this study, we utilized two independent cohorts of PNET tissue samples to investigate the infiltration of TAMs and its impact on tumor progression and metastasis. Our data clearly show that infiltrating TAMs are significantly correlated to tumor hallmarks such as angiogenesis, proliferation and metastasis. In addition, this study introduces liposomal clodronate as new therapeutic tool to target macrophages in pancreatic neuroendocrine tumors. Liposomal clodronate by depleting TAMs significantly impaired angiogenesis in the RipTag2 genetic mouse model of PNET. Our data suggest that pharmacological depletion of TAMs could serve as a suitable new therapeutic avenue for patients with unresectable disease. However, dual targeting of angiogenesis by simultaneous use of the clinically established multi-tyrosine kinase inhibitor sunitinib and liposomal clodronate in RIP1-Tag2 mice failed to show synergistic antitumor or antiangiogenic efficacy.
Recently, TAMs were assessed in human PNETs samples with the degree of infiltration strongly correlating to proliferative activity, tumor grade and stage. 23 However, this study included only a small heterogeneous patient cohort with 22 functional nonactive (NF) and 5 functionally active (FA) PNETs without detailed characterization. TAM infiltration was only investigated in primary tumor samples. In our study, we used two independent cohorts of PNET including both primary tumors and metastases. In the first cohort, we could detect a remarkable difference between TAMs in primary tumors and distant metastases. However, this cohort also included heterogeneous tumor entities, both functionally active and nonactive. Therefore, we aimed to confirm our data in a more homogeneous PNET cohort and used a TMA comprising benign and malignant insulinoma tissues including lymph node and liver metastases. Hereby, we could confirm the association between TAM infiltration, tumor progression and grading. In analogy to our findings, Wei et al. in 2014 reported a positive association between TAM infiltration and recurrence in a small cohort of 38 patients after curative resection of NF-PNETs. 24 In this report, TAM infiltration was only compared semiquantitatively. In contrast, in our series comprising >100 human samples, TAM infiltration was quantified in absolute numbers per HPF which to our knowledge represents the largest study on TAMs in human PNET tissues. In various cancer models, TAMs have been shown to affect angiogenesis. 38 TAMs secrete a variety of proangiogenic growth factors, most prominently the vascular endothelial growth factor (VEGF), a cardinal mediator of tumor angiogenesis. 39, 40 TAM-induced upregulation of VEGF results in the so-called angiogenic switch that leads to enhanced microvessel formation and tumor progression. Our study clearly corroborates these findings showing a significantly reduced microvessel density following macrophage depletion.
Several trials are currently ongoing to evaluate antibodyor small-molecule-based strategies targeting macrophagederived proteins such as CCR2 or CSF1 that, however, might be associated with a considerably toxicity. In contrast, systemic application of macrophage-modulating bisphosphonates represents a promising therapeutic avenue with a favorable toxicity profile. This "drug repurposing" approach makes use of a compound which has been used in clinical practice of osteoporosis treatment for many years.
Clodronate coated in liposomes has been widely used as experimental tool for macrophage depletion in several disease models including autoimmune disorders, atherosclerosis and cancer. 41 The use of liposomal clodronate has been reported in several xenograft tumor models. 42, 43 Recently, we depleted TAMs by liposomal clodronate in a mouse model of pancreatic adenocarcinoma (PDAC). 33 Interestingly, in this model liposomal clodronate induced a significant decrease in metastasis formation. The size of the primary tumor, however, was only reduced to a minor extent. 33 We speculate that different angiogenesis patterns in PDAC versus PNET might be responsible for this difference: PDAC primary tumors are largely hypovascular which limit the antiangiogenic effect of liposomal clodronate on the primary tumor. In these tumors, the effect of premetastatic niches in target organs liver and lung might be more important. In contrast, PNET tissues are highly vascularized resulting in an increased efficacy of antiangiogenic strategies in PNET tumors including therapeutic targeting of TAMs.
The depletory effect on macrophages appears to be a group effect and not to be restricted to liposomalencapsulated clodronate. It has also been observed with other bisphosphonates such as zoledronate which has been shown to reduce viability of macrophages without affecting cancer cells in vitro and to diminish intratumoral macrophages in xenograft models in vivo. 44, 45 However, liposomal coating of drugs such as clodronate enhances their phagocytosis by cells such as macrophages, thereby increasing therapeutic efficacy. Generally, nanoparticle-coating of cytotoxic drugs such as doxorubicin or irinotecan with liposomes is increasingly used to decrease toxicity and improve tolerability. 46, 47 Despite of the pronounced effects of liposomal clodronate action on microvessel density and tumor progression, we failed to detect a significant synergism of liposomal clodronate with the antiangiogenic multikinase inhibitor sunitinib, which has been shown to target several VEGF-dependent signaling pathways in vitro and to significantly improve progression-free survival in PNET patients. This is in contrast to a report using xenograft HCC mouse models in which zoledronate was shown to overcome sunitinib-and sorafenib-induced IL12-dependent prometastatic resistance mechanisms. 48 The reasons for the lack of synergism in our in vivo model have yet to be elucidated. Previously, we have shown that liposomal clodronate leads to a pronounced downregulation of VEGF as main secretion product of TAM. 33 It may be speculated that both macrophage depletion and sunitinib application predominantly affect VEGF-dependent angiogenic pathways which could explain in part the lack of synergism in the highly VEGF-dependent PNET model.
Taken together, our data indicate that TAM plays a major role in tumor progression of pancreatic neuroendocrine tumors. Pharmacological macrophage depletion by liposomal clodronate leads to a pronounced antiangiogenic effect decreasing tumorigenesis and tumor progression, which could represent a new therapeutic avenue for this highly angiogenic tumor entity. Based on our data, further studies are warranted to evaluate the role of bisphosphonates alone or in combination with established therapies such as somatostatin analogs or cytotoxic drugs in pancreatic neuroendocrine tumors.
